Genenta Science S.p.A.

NasdaqCM:GNTA Stock Report

Market Cap: US$40.6m

Genenta Science Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Pierluigi Paracchi

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure12.5yrs
CEO ownership9.8%
Management average tenure4.3yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Analysis Article • Jan 26

We're Keeping An Eye On Genenta Science's (NASDAQ:GNTA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 21

We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 10

We're Not Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 09

We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 25

Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach

H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science (NASDAQ:GNTA) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer. The firm has a $25 price target (269% upside based on Friday's close). Genenta shares are down 9% in early Monday afternoon tradig. Analyst Emanuela Branchetti said that the company's technology is "based on the ex-vivo lentiviral vector (LVV) mediated modification of autologous hematopoietic stem/progenitor cells (HSPCs) that deliver immunomodulatory molecules directly to the tumor." She highlighted four advantages/differentiating factors of Genenta's (GNTA) tech: 1. It focuses on a type tumor-associated myeloid cells (TEMs) that known to be involved in promoting angiogenesis and tumor growth; 2. It is built in a way that controls transgene expression and avoids off-target and systemic toxicity; 3. It has potential for long-tern durabiklity given the use of HSPCs; and 4) It is agnostic so it could potentially be used in a wide variety of cancers. Genenta's (GNTA) lead candidate, temferon, is currently in phase 1/2a for glioblastoma multiforme. It is idesigned to deliver IFN-α only at the tumor site. A data update is expected in this half of the year with enrollment completion in H1 2023. A phase 2 study is planned for H2 2023.
Analysis Article • Mar 18

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Pierluigi Paracchi (53 yo)

12.5yrs
Tenure

Mr. Pierluigi Paracchi, DEc, is Co-Founder of Genenta Science S.p.A., serves as its Chief Executive Officer and was its General Manager and served as its Chairman until November 2020 and was its Vice Chair...

Leadership Team

NamePositionTenureCompensationOwnership
Pierluigi Paracchi
Co-Founderno datano data9.76%
$ 4.0m
Luigi Naldini
Co-Founder & Chairman of Scientific Advisory Boardno datano data5.88%
$ 2.4m
Bernard Gentner
CO-Founder & Scientific Advisory Board Memberno datano data2.94%
$ 1.2m
Richard Slansky
Principal Financial & Accounting Officer5.2yrsno data0.094%
$ 38.1k
Gianfranco Nigris
Vice President Corporate Developmentno datano datano data
Francesco Galimi
Chief Medical Officerless than a yearno data0%
$ 0
Stefania Mazzoleni
Director of Program Development3.5yrsno data0.13%
$ 52.2k
Barbara Regonini
Director of Finance5.5yrsno data0%
$ 0
4.3yrs
Average Tenure
53yo
Average Age

Experienced Management: GNTA's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pierluigi Paracchi
Co-Founder12.5yrsno data9.76%
$ 4.0m
Luigi Naldini
Co-Founder & Chairman of Scientific Advisory Boardno datano data5.88%
$ 2.4m
Bernard Gentner
CO-Founder & Scientific Advisory Board Memberno datano data2.94%
$ 1.2m
Francesco Galimi
Chief Medical Officer1.3yrsno data0%
$ 0
Kenneth Anderson
Member of Scientific Advisory Boardno datano datano data
Richard Flavell
Member of Scientific Advisory Board5.2yrsno datano data
Patrick Wen
Member of Scientific Advisory Board5.2yrsno datano data
Miriam Merad
Member of Scientific Advisory Board5.2yrsno datano data
Wolf-Herve Fridman
Member of Scientific Advisory Board5.2yrsno datano data
Michele De Palma
Member of Scientific Advisory Boardno datano datano data
Lisa Coussens
Member of Scientific Advisory Boardno datano datano data
Carlo-Alberto Nicchio
Chairman of the Board of Statutory Auditors5.2yrsno datano data
5.2yrs
Average Tenure
58yo
Average Age

Experienced Board: GNTA's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 15:56
End of Day Share Price 2026/07/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genenta Science S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Charles ButlerRoth Capital Partners